Press-release for stocks related to cancer

| Email alert Add to watchlist
lung cancer immunotherapy for collaboration saga response biomarkers

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K

| -3.83% | O: -3.83% H: 0.0% C: 0.0%
breast cancer preclinical for

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
CMPX | $1.48 -0.67% -0.68% 230K

| -13.53% | O: 2.06% H: 0.0% C: 0.0%
association tumors cancer research for meeting therapeutics negative

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120

| Email alert Add to watchlist
tg4050 first cancer benefits

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
ICAD | $1.54 -3.15% -3.25% 68K

| -2.53% | O: 5.7% H: 11.98% C: 7.78%
precision breast health cancer risk solutions for

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K

| -2.13% | O: 1.77% H: 0.0% C: 0.0%
breast cancer system

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
IPSC | $3.06 2.86% 2.78% 110K

| -18.25% | O: -1.59% H: 8.87% C: 7.8%
association cancer cell research preclinical for meeting technology therapeutics therapy platform

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M

| -7.96% | O: 2.12% H: 4.35% C: 2.25%
bladder positive cancer trial

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
ICAD | $1.54 -3.15% -3.25% 68K

| -3.75% | O: 1.25% H: 18.52% C: 17.28%
breast cancer

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
Published: 2024-04-02 (Crawled : 12:30) - biospace.com/
LH M | $201.48 1.02% 0.0% 770K

| -6.87% | O: -0.1% H: 0.01% C: -1.94%
precision association cancer research meeting

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M

| -6.76% | O: -0.6% H: 2.8% C: 2.25%
cancer trials trial

NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
NEO | $13.54 -1.67% -1.7% 770K

| -10.75% | O: 1.45% H: 1.3% C: -1.17%
cancer care meeting

Ambetter from Sunshine Health and Tampa Bay Buccaneers Tackle Colorectal Cancer During Colorectal Cancer Awareness Month
Published: 2024-03-26 (Crawled : 23:00) - prnewswire.com
CNC | $75.15 1.9% 0.0% 2.7M

| -3.11% | O: 0.63% H: 0.82% C: 0.38%
bay health cancer

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

| -2.86% | O: -100.0% H: NaN% C: Infinity%
NVS | $94.36 1.93% 0.0% 2.3M

| -1.94% | O: -0.08% H: 0.15% C: -0.44%
LLY | News | $726.31 -2.63% -0.04% 3.5M

| -5.75% | O: 0.06% H: 0.96% C: 0.26%
CAH | $108.19 2.07% 0.0% 1.5M

Distribution Services

| -2.54% | O: 0.02% H: 0.73% C: -0.02%
LNTH | $63.8 2.36% 2.3% 800K

| 8.12% | O: 0.1% H: 1.98% C: -0.08%
reach cancer treatment market

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
Published: 2024-03-25 (Crawled : 12:00) - biospace.com/
BDSX | $1.24 -0.8% -0.81% 48K

| -9.42% | O: 4.35% H: 5.56% C: 0.0%
cancer research agreement

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
PMVP | $1.61 -0.62% -0.62% 480K

Commercial Services

| -3.59% | O: 5.99% H: 1.13% C: -4.52%
presentation cancer pharmaceuticals meeting advanced

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published: 2024-03-18 (Crawled : 12:30) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M

| -4.74% | O: 0.19% H: 1.46% C: 0.48%
cancer trial

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
Published: 2024-03-16 (Crawled : 16:20) - prnewswire.com
LH M | $201.48 1.02% 0.0% 770K

| Email alert Add to watchlist
precision cancer research impact diagnostics

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M

| -13.79% | O: -0.75% H: 4.38% C: 2.7%
test health cancer study

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
MDXH | $2.37 1.72% 1.69% 48K

| Email alert Add to watchlist
test genetic cancer offering

← Previous
1
2
3
4
5
6
7
8
9
…
28
29
Next →

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M

Finance

EGOX | $0.0515 43.06% 30.1% 330M

OLB 4 | $0.33 -14.95% 25.53% 840K